Published in Chest on October 28, 2010
Bacterial complications of respiratory tract viral illness: a comprehensive evaluation. J Infect Dis (2013) 2.29
Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations. Lung India (2012) 1.40
Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet (2015) 1.11
Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note. Int J Chron Obstruct Pulmon Dis (2012) 1.08
Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD. Respir Res (2012) 1.07
The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease. Caspian J Intern Med (2012) 1.04
Novel outcomes and end points: biomarkers in chronic obstructive pulmonary disease clinical trials. Proc Am Thorac Soc (2011) 0.92
Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Med (2017) 0.91
Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD. Wien Klin Wochenschr (2015) 0.90
A novel host-proteome signature for distinguishing between acute bacterial and viral infections. PLoS One (2015) 0.86
Serum C-reactive protein as a diagnostic biomarker in dogs with bacterial respiratory diseases. J Vet Intern Med (2013) 0.83
When should acute exacerbations of COPD be treated with systemic corticosteroids and antibiotics in primary care: a systematic review of current COPD guidelines. NPJ Prim Care Respir Med (2015) 0.82
Usefulness of plasma procalcitonin to predict severity in elderly patients with community-acquired pneumonia. Tuberc Respir Dis (Seoul) (2013) 0.82
Infection biomarkers in primary care patients with acute respiratory tract infections-comparison of Procalcitonin and C-reactive protein. BMC Pulm Med (2016) 0.81
Diagnostic and prognostic value of soluble CD14 subtype (Presepsin) for sepsis and community-acquired pneumonia in ICU patients. Ann Intensive Care (2016) 0.80
Neuron-specific enolase as a novel biomarker reflecting tuberculosis activity and treatment response. Korean J Intern Med (2016) 0.79
Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS One (2015) 0.78
The Diagnostic Value of Serum C-Reactive Protein for Identifying Pneumonia in Hospitalized Patients with Acute Respiratory Symptoms. J Biomark (2016) 0.77
Serum procalcitonin is not an early marker of pulmonary exacerbation in children with cystic fibrosis. Eur J Pediatr (2011) 0.77
Computer-aided diagnosis of pneumonia in patients with chronic obstructive pulmonary disease. J Am Med Inform Assoc (2013) 0.76
Systemic signs of neutrophil mobilization during clinically stable periods and during exacerbations in smokers with obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.76
The association of serum procalcitonin and high-sensitivity C-reactive protein with pneumonia in elderly multimorbid patients with respiratory symptoms: retrospective cohort study. BMC Geriatr (2016) 0.75
Serum procalcitonin and infective exacerbations of asthma. Chest (2011) 0.75
Procalcitonin guidance for reduction of antibiotic use in patients hospitalized with severe acute exacerbations of asthma: a randomized controlled study with 12-month follow-up. Crit Care (2014) 0.75
Community-acquired pneumonia: identification and evaluation of nonresponders. Ther Adv Infect Dis (2013) 0.75
Procalcitonin and CRP as Biomarkers in Discrimination of Community-acquired Pneumonia and Exacerbation of COPD. J Med Biochem (2017) 0.75
Serum enolase-2, high-sensitivity C-reactive protein, and serum cholesterol in smear-positive drug-naïve pulmonary tuberculosis. J Res Med Sci (2017) 0.75
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2007) 47.86
Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax (2003) 9.54
Validation of a modified Early Warning Score in medical admissions. QJM (2001) 9.53
Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatr (2007) 6.70
The global burden of asthma. Chest (2006) 5.74
Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet (2004) 5.49
BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax (2009) 5.23
The changing epidemiology of resistance. J Antimicrob Chemother (2009) 5.13
Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA (2010) 4.57
Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest (2007) 4.21
Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med (2006) 4.15
Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med (2006) 4.11
British Guideline on the Management of Asthma. Thorax (2008) 4.10
Changing use of antibiotics in community-based outpatient practice, 1991-1999. Ann Intern Med (2003) 4.08
Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax (2001) 3.38
Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ (2005) 2.66
Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol (2009) 2.62
Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest (2004) 2.40
C-reactive protein. A clinical marker in community-acquired pneumonia. Chest (1995) 1.77
Trends in antibiotic prescribing for adults in the United States--1995 to 2002. J Gen Intern Med (2005) 1.75
Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest (2010) 1.63
International statistical classification of diseases and related health problems. Tenth revision. World Health Stat Q (1988) 1.60
Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax (2009) 1.56
Procalcitonin as a marker of bacterial infection in the emergency department: an observational study. Crit Care (2003) 1.46
C-reactive protein as a marker of infection in critically ill patients. Clin Microbiol Infect (2005) 1.43
Sequential changes of inflammatory and nutritional markers in patients with community-acquired pneumonia. Scand J Clin Lab Invest (1997) 1.41
Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2006) 1.40
Routine antibiotics in hospital management of acute asthma. Lancet (1982) 1.33
Aetiology and prediction of pneumonia in lower respiratory tract infection in primary care. Br J Gen Pract (2007) 1.32
Etiology of asthma exacerbations. J Allergy Clin Immunol (2008) 1.31
Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon? Proc Am Thorac Soc (2004) 1.27
Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care (2007) 1.19
Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir Res (2007) 1.12
Clostridium difficile: controversies and approaches to management. Curr Opin Infect Dis (2009) 1.04
Decrease in expenditures and selected nosocomial infections following implementation of an antimicrobial-prescribing improvement program. Clin Perform Qual Health Care (1998) 0.99
Stability in community-acquired pneumonia: one step forward with markers? Thorax (2009) 0.90
C-reactive protein to distinguish pneumonia from acute decompensated heart failure. Clin Biochem (2009) 0.86
C-reactive protein velocity following antibiotics in patients with chronic obstructive pulmonary disease exacerbation and community acquired pneumonia. Eur J Intern Med (2009) 0.83
Relationship between asthma medication and antibiotic use. Chest (2001) 0.82